Bold claim first: GLP-1 drugs like Ozempic and Wegovy may carry an underappreciated side effect that could affect breathing. But here’s the full picture and why this matters to you.
GLP-1 medications, including semaglutide—the active ingredient in Ozempic and Wegovy—are widely praised for their benefits in diabetes management and weight loss. Yet, as with any powerful medicine, hidden or less obvious side effects can emerge over time. New research suggests a potential link between GLP-1 use and a slightly increased risk of chronic cough for some patients. In a study led by researchers at the University of Southern California and collaborators, people taking GLP-1 therapies for type 2 diabetes appeared more likely to develop chronic cough than those on other diabetes treatments. This finding signals the need for deeper investigation into why this happens and who might be most at risk.
Could chronic cough be a consequence of GLP-1 treatment?
The typical side effects of GLP-1 drugs are largely gastrointestinal—nausea, vomiting, and constipation are common. Some studies have also suggested a higher risk of gastroesophageal reflux disease (GERD) and acid reflux, likely because GLP-1s slow gastric emptying. GERD and acid reflux themselves can cause chronic cough, which is part of why researchers are exploring whether GLP-1 use might be linked to cough independently of reflux. However, no study before this had specifically addressed a direct GLP-1–cough relationship.
In the analysis, researchers examined electronic health records from 70 health care organizations, covering nearly 500,000 GLP-1 users with diabetes and a comparison group of about 1.6 million people on other medications. The overall finding: GLP-1 users had about a 12% higher risk of developing a new chronic cough compared with users of other diabetes drugs. When breaking down drug classes, there wasn’t a clear higher risk for any specific non-GLP-1 class like SGLT2 inhibitors. Notably, the increased cough risk persisted even after excluding individuals with a prior GERD diagnosis.
What this means for patients and clinicians
It’s important to emphasize that this study is observational. That means it cannot prove that GLP-1 medications cause chronic cough; it can only show an association. The authors themselves call for further research to confirm the existence, strength, and mechanisms of this potential link.
The bottom line: GLP-1 therapies have transformed obesity treatment and diabetes care for many people, delivering meaningful benefits. At the same time, ongoing safety monitoring remains essential. If this potential side effect is confirmed, clinicians can better anticipate, recognize, and manage cough in patients taking GLP-1 medications, ensuring that treatment benefits continue to outweigh risks.
Where this leaves us moving forward
- Continued observational studies and, if feasible, prospective trials to establish causality and identify who is most at risk.
- Exploration of the biological mechanisms behind any observed association, which could inform prevention or management strategies.
- Open dialogue between patients and clinicians about new or persistent respiratory symptoms after starting GLP-1 therapy.
Whether you’re considering GLP-1 therapy or already on it, staying informed and maintaining regular follow-ups with a healthcare provider is key. If new cough or respiratory symptoms arise after beginning GLP-1 treatment, share them with a clinician promptly so they can assess whether any adjustments to therapy are appropriate.
What’s your take on this emerging potential side effect? Do you think this changes how you view GLP-1 medications, or do you see it as a manageable risk within the broader benefits? Share your thoughts in the comments.
